Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)

NCT03288870 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

218

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer Stage IIIB
Non-Small Cell Carcinoma of Lung, TNM Stage 4

Interventions

DRUG: BCD-100
DRUG: Docetaxel

Sponsor

Biocad